Intestinal Inflammation Models
PepT1-mediated uptake of KPV was followed by lower intestinal inflammation scores in DSS- and TNBS-induced colitis models.

Inflammation Pathway Studies
Free Shipping on orders over $200
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
The Eon standard
Your results are only as good as your compound. Every lot of KPV is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement. Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
KPV is a three amino acid peptide: lysine, proline, and valine. It is the tail end of a larger hormone called alpha-MSH. That tail carries the anti-inflammatory part of the sequence but not the part that affects skin color. Studies have measured its effect on NF-kB, a signaling pathway involved in inflammation. Its small size lets it enter cells through routes that larger peptides cannot use.
α-MSH-derived tripeptide (α-MSH 11-13)
The numbers that define KPV and how it is being studied. For laboratory research use only.
Lys-Pro-Val (α-MSH 11-13)
Master inflammatory regulator
Carried into cells by the PepT1 transporter
The pathways KPV acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
At nanomolar concentrations, lower NF-κB and MAP-kinase pathway activation is measured in vitro. NF-κB is a principal regulator of inflammatory gene expression, and reduced secretion of TNF-α, IL-6 and IL-1β is recorded alongside.
Research shows KPV is taken up by cells via the PepT1 di/tripeptide transporter, which is expressed on immune cells and intestinal epithelial cells. This transporter-mediated uptake allows KPV to act intracellularly on inflammatory signaling.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH 11-13). Most of α-MSH's anti-inflammatory activity has been attributed to this fragment, which also shows antimicrobial activity in vitro.
The main areas KPV is being studied for - and the study-reported figures behind them.
PepT1-mediated uptake of KPV was followed by lower intestinal inflammation scores in DSS- and TNBS-induced colitis models.
KPV is studied as the C-terminal tripeptide that carries much of α-MSH's anti-inflammatory and immunomodulating activity.
In a rabbit corneal model, topical KPV produced complete re-epithelialization by 60 hours, with a mechanism that may involve nitric-oxide signaling.
KPV shows antimicrobial effects against Staphylococcus aureus and Candida albicans across a broad concentration range in published research.
An interactive 3D model rendered from the compound record - rotate and explore its structure.
C16H31N5O4
| Chemical Name | KPV (Lys-Pro-Val) |
| Sequence | L-Lysyl-L-Prolyl-L-Valine (α-MSH 11-13) |
| Molecular Weight | 342.43 g/mol |
| Molecular Formula | C₁₆H₃₁N₅O₄ |
| Content | 10 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
KPV is a tripeptide composed of lysine, proline and valine. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH 11-13), and much of α-MSH's anti-inflammatory and immunomodulating activity has been attributed to this fragment.
At nanomolar concentrations, KPV inhibits the NF-κB and MAP-kinase inflammatory signaling pathways. NF-κB is a master regulator of inflammatory gene expression, so suppressing it lowers production of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β in research models.
PepT1 is a di/tripeptide transporter expressed on immune cells and intestinal epithelial cells. Research shows KPV enters cells through PepT1, which allows it to act intracellularly on inflammatory signaling - a mechanism considered central to its effects in intestinal-inflammation models.
In DSS- and TNBS-induced mouse colitis models, PepT1-mediated uptake of KPV was followed by lower intestinal inflammation scores and reduced expression of pro-inflammatory cytokines including IL-1β, IL-6, IL-12, TNF-α and IFN-γ.
No. Despite roughly two decades of preclinical research across multiple organ systems, KPV has not completed human clinical trials. Research-grade KPV sold here is intended strictly for in vitro laboratory research and is not for human or veterinary use.
Lyophilized KPV should be stored at -20°C, protected from light and moisture, to preserve peptide integrity.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.